Affiliation
School of Public Health, Lanzhou University, Lanzhou 730000, ChinaIssue Date
2022
Metadata
Show full item recordAbstract
RAS is one well-established tumor-driver gene associated with cancer initiation, development, and progression. Nonetheless, comparative studies of the relevance of KRAS across diverse tumors remain sparse. We explored the KRAS expression and prognostic values in diverse cancer types via multiple web-based bioinformatics tools, including cBioPortal, Oncomine, PrognoScan, Kaplan-Meier Plotter, etc. We found that KRAS is highly expressed in various malignancies compared to normal cohorts (BRCA, CHOL, ESCA, HNSC, LIHC, LUAD, LUSC, and STAD) and less expressed in COAD, KIRC, READ, and THCA than in normal samples. We observed the dysregulation of the DNA methylation of KRAS in cancers and discovered that numerous oncogenic and tumor-suppressive transcription factors bind the KRAS promoter region. Pan-cancer analysis also showed that a high level of KRAS is associated with poor outcomes. Additionally, KRAS is remarkably correlated with the level of immune cell infiltration and tumorigenic gene signatures. In conclusion, our findings reveal novel insights into KRAS expression and its biological functions in diverse cancer types, indicating that KRAS could serve as a prognostic biomarker and is associated with immune infiltrates.Citation
Yang K, Li C, Liu Y, Gu X, Jiang L, Shi L. Prognostic and Immunotherapeutic Roles of KRAS in Pan-Cancer. Vol. 11, Cells. MDPI AG; 2022. p. 1427.Journal
CellsDOI
10.3390/cells11091427PubMed ID
35563733Additional Links
https://dx.doi.org/10.3390/cells11091427Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.3390/cells11091427
Scopus Count
Collections
Related articles
- Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
- Authors: Zhang X, Wang Y, A G, Qu C, Chen J
- Issue date: 2021
- Pan-Cancer Analysis Revealed SRSF9 as a New Biomarker for Prognosis and Immunotherapy.
- Authors: Liu J, Wang Y, Yin J, Yang Y, Geng R, Zhong Z, Ni S, Liu W, Du M, Yu H, Bai J
- Issue date: 2022
- Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
- Authors: Zhang J, Wang K, Hainisayimu T, Li H
- Issue date: 2022
- Identifies microtubule-binding protein CSPP1 as a novel cancer biomarker associated with ferroptosis and tumor microenvironment.
- Authors: Wang W, Zhang J, Wang Y, Xu Y, Zhang S
- Issue date: 2022
- Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
- Authors: Wang N, Zhu L, Wang L, Shen Z, Huang X
- Issue date: 2022